公开(公告)号：US20250042864A1

公开(公告)日：2025-02-06

申请号：US18710701

申请日：2022-11-17

Applicant: TEVA PHARMACEUTICALS INTERNATIONAL GMBH

Inventor： Sanja Matecic Musanic ,  Valentina Travancic ,  Dubravka Pavlicic ,  Marina Ratkaj

IPC: C07D263/58 ,  A61K31/423

Abstract: The present disclosure relates to a solid state form of Tafamidis, processes for preparation thereof and pharmaceutical compositions thereof.

公开(公告)号：US12180164B2

公开(公告)日：2024-12-31

申请号：US18051216

申请日：2022-10-31

Applicant: Alkermes Pharma Ireland Limited

Inventor： Julius F. Remenar ,  Laura Cook Blumberg ,  Tarek A. Zeidan

IPC: C07D215/227 ,  A61K31/496 ,  A61K31/497 ,  C07D215/22 ,  C07D263/58 ,  C07D401/12 ,  C07D401/14 ,  C07D413/10 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07F9/6558 ,  C07D241/04

Abstract: Lactam compounds of Formula I and their use for the treatment of neurological and psychiatric disorders including schizophrenia, bipolar disorder, anxiety disorder and insomnia is disclosed.

公开(公告)号：US20230339872A1

公开(公告)日：2023-10-26

申请号：US18309634

申请日：2023-04-28

Applicant: Sanford Burnham Prebys Medical Discovery Institute

Inventor： Layton H. SMITH ,  Anthony B. PINKERTON ,  Paul HERSHBERGER ,  Patrick MALONEY ,  Danielle MCANALLY

IPC: C07D277/82 ,  C07D263/58 ,  C07D513/04 ,  A61P3/00 ,  A61P9/00

CPC classification number: C07D277/82 ,  C07D263/58 ,  C07D513/04 ,  A61P3/00 ,  A61P9/00

Abstract: Provided herein are agonists of the apelin receptor for the treatment of disease. The compounds disclosed herein are useful for the treatment of a range of cardiovascular, renal and metabolic conditions.

公开(公告)号：US20230295140A1

公开(公告)日：2023-09-21

申请号：US18201715

申请日：2023-05-24

Applicant: Acucela Inc.

Inventor： Mark W. ORME ,  Edison S. ZUNIGA ,  Vladimir A. KUKSA ,  Russell Stuart CRAFT ,  Eduardo Moreno SAVEEDRA ,  Johannes Wilhelm Georg MEISSNER ,  Jacobus Antonius Joseph den HARTOG ,  Albert Cornelis DROS

IPC: C07D413/12 ,  C07D235/08 ,  C07D249/18 ,  C07D261/20 ,  C07D263/56 ,  C07D263/58 ,  C07D277/64 ,  C07D277/82 ,  C07D413/04 ,  C07D491/107

CPC classification number: C07D413/12 ,  C07D235/08 ,  C07D249/18 ,  C07D261/20 ,  C07D263/56 ,  C07D263/58 ,  C07D277/64 ,  C07D277/82 ,  C07D413/04 ,  C07D491/107

Abstract: Provided herein are compounds and methods of use thereof for the modulation of VAP-1 activity.

公开(公告)号：US20230242496A1

公开(公告)日：2023-08-03

申请号：US18001516

申请日：2021-06-15

Applicant: Icahn School of Medicine At Mount Sinai

Inventor： Jian JIN ,  Marta FILIZOLA ,  Aneel AGGARWAL ,  Samir PAREKH ,  Abhijeet KAPOOR ,  Shashidhar S. JATIANI ,  H. Umit KANISKAN ,  Jianping HU ,  Yudao SHEN ,  Fanye MENG ,  Lihuai QIN ,  Yulin HAN ,  Xufen YU ,  Chengwei ZHANG ,  Prashasti KUMAR ,  Rinku JAIN ,  Clement LEE

IPC: C07D279/16 ,  C07D265/36 ,  C07C321/28 ,  C07D249/18 ,  C07D215/48 ,  C07D239/74 ,  C07D231/56 ,  C07D277/64 ,  C07D235/06 ,  C07D335/06 ,  C07D209/34 ,  C07D263/58 ,  C07D285/14 ,  C07D217/02 ,  C07D417/12 ,  C07D239/42 ,  C07D233/64 ,  C07D403/04 ,  C07D215/38 ,  C07D239/72 ,  C07C311/46 ,  C07D295/135 ,  C07D239/48 ,  C07D235/16 ,  C07D215/227 ,  C07D295/26 ,  C07D239/54 ,  C07D405/12

CPC classification number: C07D279/16 ,  C07D265/36 ,  C07C321/28 ,  C07D249/18 ,  C07D215/48 ,  C07D239/74 ,  C07D231/56 ,  C07D277/64 ,  C07D235/06 ,  C07D335/06 ,  C07D209/34 ,  C07D263/58 ,  C07D285/14 ,  C07D217/02 ,  C07D417/12 ,  C07D239/42 ,  C07D233/64 ,  C07D403/04 ,  C07D215/38 ,  C07D239/72 ,  C07C311/46 ,  C07D295/135 ,  C07D239/48 ,  C07D235/16 ,  C07D215/227 ,  C07D295/26 ,  C07D239/54 ,  C07D405/12

Abstract: Disclosed are compounds that are chemical inhibitors of SOX11. The compounds disclosed are useful in treatment of various cancers.

公开(公告)号：US11560518B2

公开(公告)日：2023-01-24

申请号：US16754870

申请日：2018-10-10

Applicant: DAI NIPPON PRINTING CO., LTD.

Inventor： Mami Motooka ,  Ken-ichi Okuyama ,  Kazuyuki Okada ,  Terutaka Takahashi ,  Mitsuru Endo ,  Shunsuke Irie ,  Tsuyoshi Sakaguchi ,  Kei Akiyama ,  Kohei Ishikawa

IPC: C09K19/38 ,  C08F22/24 ,  G02B5/30 ,  C07D263/58 ,  C07D277/82 ,  C07D417/14 ,  C07D519/00

Abstract: A polymerizable liquid crystal compound represented by the following general formula (1): (the symbols in the general formula (1) are as described in the DESCRIPTION.)

公开(公告)号：US20220304984A1

公开(公告)日：2022-09-29

申请号：US17618829

申请日：2020-06-12

Applicant: VANDERBILT UNIVERSITY

Inventor： H. Charles Manning ,  Michael Schulte

IPC: A61K31/42 ,  C07D209/42 ,  C07D307/85 ,  C07D333/70 ,  C07D235/24 ,  C07D263/58 ,  C07D277/68 ,  C07D471/04 ,  C07D491/048 ,  C07D495/04 ,  C07D498/04 ,  C07D513/04 ,  C07D487/04 ,  C07D473/00 ,  C07D207/34 ,  C07D333/40 ,  C07D307/68 ,  C07D231/20 ,  C07D275/03 ,  C07D261/18 ,  C07D233/90 ,  C07D277/56 ,  C07D263/40 ,  C07D249/12 ,  C07D285/08 ,  C07D271/07 ,  C07D285/13 ,  C07D271/113 ,  A61K45/06 ,  A61K31/404 ,  A61K31/343 ,  A61K31/381 ,  A61K31/4184 ,  A61K31/423 ,  A61K31/428 ,  A61K31/437 ,  A61K31/4355 ,  A61K31/4365 ,  A61K31/519 ,  A61K31/52 ,  A61K31/401 ,  A61K31/341 ,  A61K31/415 ,  A61K31/425 ,  A61K31/4164 ,  A61K31/426 ,  A61K31/421 ,  A61K31/4196 ,  A61K31/433 ,  A61K31/4245

Abstract: These compounds are glutamine transporter inhibitors, e.g., alanine, serine, cysteine-preferring transporter 2 (ASCT2) inhibitors. Glutamine transporter inhibitors are useful to treat a variety of diseases, disorders, or conditions including cancer.

公开(公告)号：US20220298125A1

公开(公告)日：2022-09-22

申请号：US17830532

申请日：2022-06-02

Applicant: THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH

Inventor： Anne Marie Jeanne BOUILLOT ,  Olivier MIRGUET ,  John LIDDLE ,  Anne Louise WALKER

IPC: C07D263/58 ,  C07D413/12 ,  C07C211/13 ,  C07C211/27 ,  C07C215/10 ,  C07C223/02 ,  C07C229/26 ,  C07C279/14 ,  C07C309/30

Abstract: A compound of formula (I) or a salt thereof are provided: wherein R1, X and R3 are defined in the specification, useful in the treatment of disorders mediated by KMO such as acute pancreatitis, chronic kidney disease, other conditions associated with systemic inflammatory response syndrome (SIRS), Huntington's disease, Alzheimer's disease, spinocerebellar ataxias, Parkinson's disease, AIDS-dementia complex, amylotrophic lateral sclerosis (ALS), depression, schizophrenia, sepsis, cardiovascular shock, severe trauma, acute lung injury, acute respiratory distress syndrome, acute cholecystitis, severe burns, pneumonia, extensive surgical procedures, ischemic bowel, severe acute hepatic disease, severe acute hepatic encephalopathy or acute renal failure.

公开(公告)号：US11306056B2

公开(公告)日：2022-04-19

申请号：US17093506

申请日：2020-11-09

Applicant: Cardioxyl Pharmaceuticals, Inc. ,  The Johns Hopkins University

Inventor： John P. Toscano ,  Frederick Arthur Brookfield ,  Andrew D. Cohen ,  Stephen Martin Courtney ,  Lisa Marie Frost ,  Vincent Jacob Kalish

IPC: C07C311/00 ,  C07C317/00 ,  C07C323/00 ,  C07D231/00 ,  C07C311/48 ,  C07C317/14 ,  C07C323/67 ,  C07D213/74 ,  C07D261/10 ,  C07D263/58 ,  C07D285/125 ,  C07D295/096 ,  C07D307/82 ,  C07D333/62 ,  C07D309/12 ,  C07D317/14 ,  C07D231/18 ,  C07D333/34

Abstract: The invention relates to N-hydroxysulfonamide derivatives that donate nitroxyl (HNO) under physiological conditions and are useful in treating and/or preventing the onset and/or development of diseases or conditions that are responsive to nitroxyl therapy, including heart failure and ischemia/reperfusion injury. Novel N-hydroxysulfonamide derivatives release HNO at a controlled rate under physiological conditions, and the rate of HNO release is modulated by varying the nature and location of functional groups on the N-hydroxysulfonamide derivatives.

公开(公告)号：US20210395238A1

公开(公告)日：2021-12-23

申请号：US17466394

申请日：2021-09-03

Applicant: ACTELION PHARMACEUTICALS LTD

Inventor： Hamed AISSAOUI ,  Martin BOLLI ,  Christoph BOSS ,  Sylvia RICHARD-BILDSTEIN ,  Patrick SIEBER

IPC: C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D263/54 ,  C07D263/58 ,  C07D277/62 ,  A61P11/00 ,  A61P35/04 ,  C07D417/14 ,  C07D471/10 ,  C07D491/107

Abstract: The invention relates to 2,5-disubstituted benzoxazole and benzothiazole derivatives of Formula (I) wherein L, X, Y, and ring (A) are as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds may be useful for the prevention or treatment of diseases or disorders associated with impaired reactive oxygen species (ROS) production, and/or for the prevention or treatment of various fibrotic diseases.